Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:22 pm Sale | 2024-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Citadel Advisors LLC | 422 0.000% | -85,317 (-99.51%) | Filing History |
| 2024-12-16 9:02 pm Unchanged | 2024-12-12 | 13D | Lyra Therapeutics, Inc. LYRA | PERCEPTIVE ADVISORS LLC | 255,151 19.500% | 0 (Unchanged) | Filing History |
| 2024-11-14 7:48 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Point72 Asset Management, L.P. | 0 0.000% | -60,606 (Position Closed) | Filing History |
| 2024-11-14 5:49 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 24,082 1.800% | -86,989 (-78.32%) | Filing History |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Samsara BioCapital, L.P. | 65,635 4.980% | 10,030 (+18.04%) | Filing History |
| 2024-11-14 4:53 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Nantahala Capital Management, LLC | 14,042 1.061% | -81,004 (-85.23%) | Filing History |
| 2024-11-14 12:00 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Vestal Point Capital, LP | 0 0.000% | -60,000 (Position Closed) | Filing History |
| 2024-08-15 6:31 pm Sale | 2024-08-14 | 13D | Lyra Therapeutics, Inc. LYRA | PERCEPTIVE ADVISORS LLC | 255,151 19.500% | -0 (-0.00%) | Filing History |
| 2024-02-15 09:18 am Sale | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | PURA VIDA INVESTMENTS LLC | 32,277 3.060% | -10,869 (-25.19%) | Filing History |
| 2024-02-14 8:35 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 111,071 9.999% | 42,406 (+61.76%) | Filing History |
| 2024-02-14 6:18 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Citadel Advisors LLC | 85,739 7.900% | 27,808 (+48.00%) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Nantahala Capital Management, LLC | 95,046 8.900% | 50,630 (+113.99%) | Filing History |
| 2024-02-14 4:29 pm Unchanged | 2024-02-14 | 13D | Lyra Therapeutics, Inc. LYRA | PERCEPTIVE ADVISORS LLC | 255,151 24.300% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:18 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Point72 Asset Management, L.P. | 60,606 5.800% | 606 (+1.01%) | Filing History |
| 2024-02-13 4:34 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Vestal Point Capital, LP | 60,000 5.700% | 60,000 (New Position) | Filing History |
| 2023-11-16 5:00 pm Purchase | 2023-11-15 | 13G | Lyra Therapeutics, Inc. LYRA | Point72 Asset Management, L.P. | 60,000 5.400% | 60,000 (New Position) | Filing History |
| 2023-08-25 4:15 pm Purchase | 2022-04-12 | 13G | Lyra Therapeutics, Inc. LYRA | Samsara BioCapital, L.P. | 55,605 5.600% | 55,605 (New Position) | Filing History |
| 2023-06-12 5:23 pm Purchase | 2023-05-31 | 13G | Lyra Therapeutics, Inc. LYRA | Citadel Advisors LLC | 57,931 5.900% | 57,931 (New Position) | Filing History |
| 2023-06-09 4:20 pm Purchase | 2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA | NBVM GP LLC | 120,629 12.200% | 36,253 (+42.97%) | Filing History |
| 2023-06-02 4:16 pm Purchase | 2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA | PERCEPTIVE ADVISORS LLC | 255,151 25.800% | 72,217 (+39.48%) | Filing History |